AU2016302047B2 - Muscarinic agonists - Google Patents
Muscarinic agonists Download PDFInfo
- Publication number
- AU2016302047B2 AU2016302047B2 AU2016302047A AU2016302047A AU2016302047B2 AU 2016302047 B2 AU2016302047 B2 AU 2016302047B2 AU 2016302047 A AU2016302047 A AU 2016302047A AU 2016302047 A AU2016302047 A AU 2016302047A AU 2016302047 B2 AU2016302047 B2 AU 2016302047B2
- Authority
- AU
- Australia
- Prior art keywords
- compound according
- hydrocarbon group
- carboxylate
- ethyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1513740.9 | 2015-08-03 | ||
| GBGB1513740.9A GB201513740D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonist |
| PCT/GB2016/052384 WO2017021728A1 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2016302047A1 AU2016302047A1 (en) | 2018-02-15 |
| AU2016302047A8 AU2016302047A8 (en) | 2018-03-08 |
| AU2016302047B2 true AU2016302047B2 (en) | 2020-09-10 |
Family
ID=54063147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016302047A Active AU2016302047B2 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10548884B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3331528B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6847093B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107949384B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016302047B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2994143C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3331528T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2894855T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201513740D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017021728A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201726675A (zh) | 2015-12-23 | 2017-08-01 | 默沙東藥廠 | M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮 |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| PT3768669T (pt) | 2018-03-23 | 2023-04-24 | Pfizer | Derivados de piperazina azaspiro |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CA3155177A1 (en) * | 2019-09-25 | 2021-04-01 | Oncoarendi Therapeutics S.A. | Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine |
| AU2020361735B2 (en) | 2019-10-09 | 2024-04-18 | Novartis Ag | 2-azaspiro(3.4)octane derivatives as M4 agonists |
| CN119390705A (zh) * | 2019-10-09 | 2025-02-07 | 诺华股份有限公司 | 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物 |
| ES2983860T3 (es) | 2019-12-06 | 2024-10-25 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| EP4100410A1 (en) * | 2020-02-05 | 2022-12-14 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2025030095A1 (en) * | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008137583A (ru) | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейшн (Us) | Спиропиперидины в качестве модуляторов мускариновых рецепторов |
| WO2007100664A2 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2010049146A1 (en) | 2008-10-29 | 2010-05-06 | Grünenthal GmbH | Substituted spiroamines |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| EP2780015B1 (en) * | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| ES2694299T3 (es) * | 2013-02-07 | 2018-12-19 | Heptares Therapeutics Limited | Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4 |
| SMT202400446T1 (it) * | 2014-02-06 | 2024-11-15 | Nxera Pharma Uk Ltd | Composti aza biciclici come agonisti del recettore muscarinico |
| GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
-
2015
- 2015-08-03 GB GBGB1513740.9A patent/GB201513740D0/en not_active Ceased
-
2016
- 2016-08-03 CA CA2994143A patent/CA2994143C/en active Active
- 2016-08-03 ES ES16750221T patent/ES2894855T3/es active Active
- 2016-08-03 WO PCT/GB2016/052384 patent/WO2017021728A1/en not_active Ceased
- 2016-08-03 AU AU2016302047A patent/AU2016302047B2/en active Active
- 2016-08-03 EP EP16750221.0A patent/EP3331528B1/en active Active
- 2016-08-03 US US15/749,743 patent/US10548884B2/en active Active
- 2016-08-03 CN CN201680045225.6A patent/CN107949384B/zh active Active
- 2016-08-03 JP JP2018504993A patent/JP6847093B2/ja active Active
- 2016-08-03 DK DK16750221.0T patent/DK3331528T3/da active
-
2019
- 2019-12-27 US US16/728,762 patent/US11324738B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016302047A8 (en) | 2018-03-08 |
| US20200129496A1 (en) | 2020-04-30 |
| CN107949384A (zh) | 2018-04-20 |
| GB201513740D0 (en) | 2015-09-16 |
| US11324738B2 (en) | 2022-05-10 |
| JP2018522034A (ja) | 2018-08-09 |
| WO2017021728A9 (en) | 2017-04-27 |
| CN107949384B (zh) | 2025-02-28 |
| EP3331528B1 (en) | 2021-09-29 |
| EP3331528A1 (en) | 2018-06-13 |
| ES2894855T3 (es) | 2022-02-16 |
| JP6847093B2 (ja) | 2021-03-24 |
| WO2017021728A1 (en) | 2017-02-09 |
| HK1250139A1 (en) | 2018-11-30 |
| CA2994143C (en) | 2023-09-26 |
| DK3331528T3 (da) | 2021-10-25 |
| AU2016302047A1 (en) | 2018-02-15 |
| US20180228791A1 (en) | 2018-08-16 |
| US10548884B2 (en) | 2020-02-04 |
| CA2994143A1 (en) | 2017-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016302047B2 (en) | Muscarinic agonists | |
| JP7652832B2 (ja) | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 | |
| US12024499B2 (en) | Muscarinic agonists | |
| HK1250139B (en) | Muscarinic agonists | |
| HK40114593A (en) | Pharmaceutical compounds | |
| HK1250138B (en) | Muscarinic agonists | |
| HK1231382A1 (en) | Muscarinic receptor agonists | |
| HK1231382B (en) | Muscarinic receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 32 , NO 6 , PAGE(S) 840 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME HEPTARES THERAPEUTICS LIMTED, APPLICATION NO. 2016302047, UNDER INID (71) CORRECT THE APPLICANT NAME TO HEPTARES THERAPEUTICS LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |